JAZZ will post earnings after the bell.
Weak earnings support the argument JAZZ needs AVDL.
AVDL @ 8.40
LLNW finally seeing some action..Up 8% over the past two days
Rumors of a deal pending with major partner still swirling.[/QUOTE
JAZZ beats estimates ..a closer looks shows Xyrem with another record in sales up 8% year over year... 1.8 billion run rate.
AVDL has the replacement therapy for Xyrem /FT218 a once nightly therapeutic for narcolepsy. While JAZZ beat earnings the reason is sales of Xyrem exclusively..Again you see JAZZ has a problem if it doesn't move on AVDL...
Jazz is the largest biotechnology company you've never heard of and very aggressive on M&A.
https://www.investopedia.com/articl...m_source=yahoo&utm_medium=referral&yptr=yahoo
4th largest Jazz on the list below.
Jazz Pharmaceuticals PLC (JAZZ)
- Revenue (TTM): $2.2 billion
- Net Income (TTM): $0.5 billion
- Market Cap: $5.4 billion
- 1-Year Trailing Total Return: -30.0%
- Exchange: Nasdaq
Irish biopharmaceutical company Jazz Pharmaceuticals creates and commercializes drug products designed to address issues related to narcolepsy, psychiatry, pain management, and oncology. On March 25, the company announced FDA approval of its drug JZP-258 for the treatment of cataplexy or excessive daytime sleepiness.3
Below is a link to the deal JAZZ made with another company in 2016...JAZZ stepped up to buying a non approved top line phase 3 company mid trial.
Same situation AVDL finds itself in now.
https://www.prnewswire.com/news-rel...ire-celator-for-3025-per-share-300276751.html
who knows but the pieces fit like a glove.